News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Horus Pharma Group Launches a Nordic Subsidiary
Thursday, April 06, 2023Horus Pharma an independent French laboratory specialised in ophthalmology has taken a major step in its European expansion strategy with the opening of its new subsidiary From its base in Stockholm Sweden Horus Pharma Nordic will cover Sweden Norway...
Forcefield Therapeutics signs exclusive patent and know-how license agreement with Freeline Therapeutics
Wednesday, April 05, 2023Forcefield Therapeutics Ltd a pioneer of bestinclass therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction and Freeline Therapeutics have entered into an exclusive patent and knowhow license ag...
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
Wednesday, April 05, 2023InflaRx NV a clinicalstage biopharmaceutical company developing antiinflammatory therapeutics by targeting the complement system today announced that Gohibic vilobelimab a firstinclass monoclonal antihuman complement factor Ca antibody has been grant...
Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation
Tuesday, April 04, 2023Sandoz a global leader in offpatent generic and biosimilar medicines today announced that the European Commission EC granted marketing authorization in the European Union EU for a citratefree high concentration formulation HCF mgmL of its biosimilar...
Medigene enters Cooperative Research and Development Agreement with the National Cancer Institute to evaluate the use of Medigene’s proprietary T cell receptors in novel cell constructs
Tuesday, April 04, 2023Medigene AG an early stage immunooncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors and the National Cancer Institute NCI will collaborate to evaluate the potential of Medigenes proprietary...
Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China
Saturday, April 01, 2023Ablaze Pharmaceuticals a biotech company that is focused on developing Targeted Radiotherapy TRT to benefit cancer patients in China today announced the development plans of a firstinclass novel peptide drug candidate against GPC The proprietary GPC...
NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business
Friday, March 31, 2023NEC Corporation announced in that it would expand the application of its cuttingedge AI technologies to drug development focusing on advanced therapy as part of enhancing its healthcare business Subsequently in order to advance AIpowered personalize...
Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases
Friday, March 31, 2023Confo Therapeutics a leader in the discovery of medicines targeting Gprotein coupled receptors GPCRs today announced that it has entered a collaboration agreement with Daiichi Sankyo TSE for the discovery and development of small molecule agonists a...
Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million
Thursday, March 30, 2023Avadel Pharmaceuticals plc a biopharmaceutical company focused on transforming medicines to transform lives today announced its entry into a royalty agreement with RTW Investments LP and certain of its affiliates RTW for up to million to support the...
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma
Thursday, March 30, 2023RAPT Therapeutics Inc a clinicalstage immunologybased therapeutics company focused on discovering developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology today annou...
